The Global Antithrombin Market is expected to reach a market value of US$ 725.2 mn by 2026 from its value of US$ 490.4 mn in 2018. Key market insights have been provided by Fortune Business Insights in its report, titled “Antithrombin Market Size, Share and Global Trend By Application (Therapeutics, Research, Diagnostics & Others), Source (Human, Goat Milk), Dosage Form (Lyophilized, Liquid) & Geography Forecast till 2025”.
The report offers a comprehensive market analysis and the key factors influencing it. Antithrombin is a protein in our blood stream that prevents excessive clotting in the human body. It acts as a natural blood thinner and is a primary inhibitor of thrombin, the substance required for blood clotting. If a person is suffering from antithrombin deficiency, her blood will have a tendency to clot too much in the veins, a rare condition called as thrombosis. It can be acquired or inherited and is expected to occur in 1 in 2000 people all over the world in 2018, as per the data released by the US Department of Health and Human Services.
Segmentation
By Application
- Therapeutics
- Research
- Diagnostics & Others
By Source
- Human
- Goat Milk (Recombinant)
- Others
By Dosage Form
- Lyophilized
- Liquid
Get PDF Brochure of this Report:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antithrombin-market-100470
Increasing Number of Surgical Procedures Conducted Worldwide to Boost the Market
The global antithrombin market is poised to experience steady growth as excessive bleeding during surgical procedures has increased in occurrence. Antithrombin deficiency can lead to thromboembolism, a condition in which a clot develops in a blood vessel, breaks loose from it, and is carried by the blood stream to another vessel. This can severely affect the functioning of other organs like kidneys, brain, gastrointestinal tract, and lungs. This can create complications during and after surgeries. The market potential of antithrombins is anticipated to significantly rise on the basis of these factors.
Furthermore, the global antithrombin market is expected to gain considerable momentum during the forecast period on account of growing instances of hereditary antithrombin deficiency. Hereditary antithrombin deficiency is caused by mutations in the SERPINC1 gene. As a result, the market offers plenty of growth opportunities for those seeking to invest in it.
Therapeutics Application to be the Leading Market Segment
The therapeutics application segment commanded a staggering market share of 95.7% in 2018. Increasing prevalence of complicated conditions such as extracorporeal membrane oxygenation (ECMO) and sepsis is expected to fuel the global antithrombin market during the forecast period. The therapeutics segment is expected to reap the largest benefits as the market develops further. The goat milk segment is expected to exhibit the fastest growth till 2026 owing to its high degree of effectiveness.
Expensive Treatments May Inhibit the Market
The global antithrombin market may experience a few hurdles in its growth path on account of the high cost of treatment the disease entails. This will be a major restraining factor in low income nations and will have a negative impact on the global antithrombin market.
Intense Competition Anticipated
The global antithrombin market is getting heated up owing to a surge in competition among the key players. Market competition in this regard is being defined by new product launches and establishment of distribution networks. For example, the US-based rEVO Biologics developed ATryn, an anticoagulant antithrombin made from goat milk. Though old, the anticoagulant opened the doors for other market participants to develop medicines using genetically engineered animals.
The highest market share was held by three companies in 2018 – CSL Behring, Shire, and Grifols. The other major players identified by Fortune Business Insights include Lee Biosolutions, Scripps Laboratories, Octapharma AG, LFB USA, rEVO Biologics, and a few others.
Asia-Pacific to Occupy a Dominant Market Position
With a market revenue of US$ 179.7 mn in 2018, Asia-Pacific is expected to hold a sizeable market share in the global antithrombin market. The major factor driving the market in Asia-Pacific is the growing prevalence of congenital antithrombin III deficiency, an inherited disease. Compounding this factor are increasing life expectancy and rising demand for better quality surgical procedures that will fuel the market in the forecast period. Europe is the other region that is emerging as a promising market owing to rapid adoption of antithrombin based products.
More Trending Topics From Fortune Business Insights@